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Abstract: Model-based approaches for combining gene expression data from multiple high throughput platforms can be sensitive 
to technological artifacts when the number of samples in each platform is small. This paper proposes simple tools for quantifying 
  concordance in a small study of pancreatic cancer cells lines with an emphasis on visualizations that uncover intra- and inter-platform 
variation. Using this approach, we identify several transcripts from the integrative analysis whose over-or under-expression in   pancreatic 
cancer cell lines was validated by qPCR.
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Introduction
The ability of high-throughput gene expression tech-
nologies to reproducibly capture differences between 
populations stratified by a clinical covariate, such as 
cancer metastasis, is difficult when the sample size is 
small. When increasing the sample size of a study is 
not possible due to limited resources, approaches that 
integrate information from otherwise similar studies, 
though possibly employing different high-throughput 
technologies, may be explored.
Combining  data  from  multiple  studies  is  often 
  discussed in the context of its potential to increase the 
statistical power for detecting differentially expressed 
genes.1  An  additional  advantage  of  a    cross-study 
  analysis is the potential to reduce spurious associa-
tions driven by an artifact in a single platform or study. 
Statistical approaches for integrating gene expression 
data from multiple high-throughput   platforms include 
combining measures of statistical significance, such 
as  P-values,  calculated  independently  from  the 
  individual  studies,2  Bayesian  models  for  the  joint 
distribution of gene expression across studies,3,4 and 
the derivation of a study-independent scale, such as 
posterior probabilities of differential expression,5 to 
which standard single-study methods can be applied.6 
When  the  sample  size  in  the    individual  studies  is 
small, nonparametric approaches that use the rank of 
fold-changes in expression across a binary phenotype 
may provide additional robustness to technological 
artifacts and outliers.7–9 This paper further explores 
the joint analysis of multiple platforms when the sam-
ple size in the individual studies is small.
The dataset used in this analysis consists of two 
primary  (Capan2  and  Panc1)  and  two  metastatic 
(Capan1 and Hs766t) cell lines that were measured by 
3 high-throughput technologies for gene expression: 
two-color cDNA arrays, Affymetrix oligonucleotide 
arrays, and serial analysis of gene expression (SAGE). 
The data was originally described elsewhere.10 See11 
for a discussion of the technologies.11 As late   detection 
of pancreatic adenocarcinoma is a primary reason for 
its  poor  prognosis,  the  study  of  pancreatic  cancer 
  progression is a biologically relevant problem. Stage-
specific genetic alterations can be useful markers for 
the more agressive phenotype.12 The heterogeneity of 
the pancreatic cancer phenotype and the small num-
ber of samples motivated an approach that integrated 
information from the multiple technologies.
Methods
Preprocessing
Our  analysis  uses  previously  collected  data  from 
  metastatic pancreatic cancer cell lines Capan1 (c1) 
and  Hs766t  (ht),  and  primary  pancreatic  cancer 
cell lines Capan2 (c2) and Panc1 (p1). See10 for a 
description of the cell lines.10 Inferences regarding 
differential expression depend crucially on appropri-
ate   pre-processing and normalization. Although we 
strongly prefer unprocessed data to processed data, 
this was not possible for the Affymetrix   platform. We 
used  Mas  5.0  normalized Affymetrix  data  without 
  further processing. SAGE libraries were   standardized 
to  tags  per  50,000.  cDNA  data  was  normalized 
by  loess  smoothing  of  M  versus  A  scatterplots13 
without    subtracting  local  estimates  of  background 
  fluorescence.14  Expression  measures  were  trans-
formed to the log2 scale and centered by the gene-
specific means in each study.
Common gene set
Following  normalization,  the  studies  were  merged 
to produce a common set of features measured in all 
three platforms. Note that the unit of measure for the 
combined analysis need not be genes. For instance, 
one may map probe identifiers in each platform to 
exons using the sequence information of the probes, 
and then treat exon-level measures of expression as 
the  unit  to  be  compared  across  technologies.15 As 
probes in an Affymetrix probe-set may map to more 
than one exon, one could pre-process and normal-
ize  probe-level  intensities  using  redefined  probe-
sets.16   Alternatively, one may map features in each 
  platform to a Unigene cluster or refSeq identifiers. 
For this dataset, probe-level data was not available 
in the Affymetrix platform and the choice for cross-
  referencing  annotations  was  limited.  We  therefore 
mapped  probes  (or  probesets)  in  each  platform  to 
Unigene  Cluster  Identifiers  (build  180)  using  the 
R package MergeMaid.17 One-to-many mappings of 
probes to Unigene clusters were excluded and many-
to-one mappings were averaged.
Gene filtering
As SAGE can in theory detect the mRNA transcripts 
for any gene, we only required membership in the 
Affymetrix  and  cDNA  platforms.  Specifically,  any 
gene present in Affymetrix and cDNA that was not Cross-platform microarray analysis
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detected by SAGE was assigned a count of zero in 
SAGE. For the cDNA and Affymetrix platforms, we 
excluded genes with very low levels of expression in 
2 or more of the cell lines to limit the influence of low 
abundance  genes  in  the  combined  analysis.  While 
more  aggressive  filtering  strategies  can  improve 
measures  of  cross-study  correlation,  inter-platform 
discordance can arise from technological as well as 
biological sources of variation (eg, probes from dif-
ferent platforms may hybridize to different regions 
of a gene that is alternatively transcribed). After the 
above filtering, 3117 genes remain and were used in 
the cross-study analysis of differential expression.
Concordance
Concordance  of  the  log-fold  changes  across  plat-
forms  were  assessed  using  Spearman  correlation 
coefficients, a rank-based alternative to the Pearson 
correlation coefficient, and Kappa statistics. Kappa 
statistics regard the high-throughput platforms as dif-
ferent observers of gene expression and can be used 
to quantify inter-observer agreement using qualitative 
measures of differential expression. Using a quan-
tile of the fold-change distribution in each platform, 
the observed fold-changes were classi-fied as   under-, 
none-, and over-expressed in each of the possible pair-
wise combinations of platforms. We used   qualitative 
categories  of  under-expressed,  over-expressed,  and 
not differentially expressed, yielding a 3 × 3 table 
with elements on the diagonal corresponding to the 
number of genes that have the same qualitative cat-
egory of differential expression in the two platforms. 
We adopted a weighted Kappa statistic that penalizes 
discordance of over versus under-expression.18
Results
Spearman correlations of the log2-transformed inten-
sities of cDNA and Affymetrix ranged from 0.21–0.57 
(Fig. 1). Correlations of cDNA and Affymetrix inten-
sities  to  standardized  SAGE  counts  ranged  from 
0.0–0.32, likely reflecting the greater dissimilarity in 
the technologies.
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Figure 1. For each platform, we calculated all 6 pairwise combinations of fold changes in expression between the four cell lines. Panels are color-coded 
to indicate whether the log2 fold change was between primary-primary (blue), metastatic-primary (yellow background), or metastatic-metastatic (green) 
cell lines.Scharpf et al
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As  a  potentially  more  robust  alternative  to  the 
Spearman  correlation  coefficient,  we  also  assessed 
inter-platform concordance using qualitative catego-
ries of differential expression using a weighted Kappa 
statistic. We avoided characterizing agreement using 
a single arbitrary threshold by plotting the weighted 
Kappa  over  a  range  of  thresholds  based  on  quan-
tiles of the fold-change distribution (Fig. 2). Kappa-
statistics estimated from absolute fold-changes can 
be used to relax the assumption that the percentage 
of  over-  and  under-expressed  genes  are  the  same, 
but were qualitatively similar to the Kappa plots in 
Figure 2 in the pancreatic cancer dataset (not shown). 
Again, the two intensity-based platforms (cDNA and 
Affymetrix)  have  the  highest  inter-platform  agree-
ment (Kappa . 0.4). Together with the Spearman 
correlation coefficients, the small Kappa in several 
of the pancreatic cancer cell line comparisons reflects 
(i) our decision to minimize data filtering prior to the 
combined  analysis,  (ii)  the  absence  of  technologi-
cal replicates for quality control measures, (iii) the 
biological heterogeneity of the pancreatic cancer cell 
lines through passage, (iv) different laboratories per-
forming the experiments (batch effects), and (v) the 
non-overlapping technologies. To the extent that each 
platform is measuring a similar biological process, 
concordant findings in multiple platforms may reduce 
the occurrence of spurious single-study associations. 
With this view, we explore rank-based approaches 
for  prioritizing  a  gene  list  and  provide  visualiza-
tions that make the cross-platform variability in the 
ranks transparent.
Rank-based approaches for cross-study analysis of 
differential  expression  in  high-throughput  microar-
ray platforms have been proposed by others.19,8 An 
implementation of these approaches is available in the 
R package RankProd. For this dataset, we ranked the 
average fold changes for the metastatic to primary can-
cer comparisons, and summarized the study-specific 
ranks by the arithmetic mean. By contrast, RankProd 
computes  the  geometric  mean  of  the  ranked  fold 
changes.19,8 An advantage of using a geometric mean 
(instead of an arithmetic mean) is that the ranking 
will be more robust to unusual observations. In our 
dataset, there are four possible pairwise comparisons 
within a study and a given cell line is represented in 
half of the possible comparisons. In the absence of 
a better gene-specific measure of unusual, the effect 
of the arithmetic mean is that genes with higher vari-
ance in the ranks within and across studies will tend 
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Figure 2. Genes were classified as under-expressed (fold-change , q), not differentially expressed (q , fold-change  1 − q), or over-expressed 
  (fold-change . 1 − q), where q is a quantile of the fold-change distribution. On the vertical axis is a weighted kappa-statistics that penalizes discordance 
(over-expressed in platform 1, under-expressed in platform 2).Cross-platform microarray analysis
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to be positioned further down the list. See19 for a more 
detailed discussion of the when an arithmetic mean 
may be preferable.19 Overall, we expect that the two 
approaches will be qualitatively similar for the set of 
genes with low variance in the rankings.
While the rank of the average rank can be used to 
prioritize genes that show on average large fold changes 
in expression, such a statistic hides the variability in the 
ranks. We adopted the range of the ranks for each gene 
as a measure of spread. Of interest are genes that are 
consistently over (under)-expressed in metastatic rela-
tive to primary cell-lines as reflected by a small range 
of ranks and a large (small) average rank. In order to 
obtain a null distribution, we permuted the vector of 
ranked average fold changes in each study indepen-
dently of the other studies and recomputed the range of 
ranks and the rank of the average ranks. Repeating the 
permutation a large number of times, we obtained a null 
distribution for the range of ranks for each rank of the 
average rank. Figure 3 plots the observed range (y-axis) 
against the rank of the average rank (x- axis) as blue 
points. The background is shaded by the density of the 
null distribution for the range of ranks, where lighter 
shades of gray denote more densely plotted regions 
of the null. Boxplots of the null distribution at the far 
left and far right of this plot can be useful for magnify-
ing the lowest and highest average ranks, respectively 
(Fig. 4). In addition to plotting the null distribution for 
the range of ranks, we flagged genes for which the log 
fold change between the 2 primary cell lines or the 
2 metastatic cell lines exceeded 3 in one or more of the 
platforms. Again, a motivation for the flag is that the 
average fold-change can hide the underlying variability 
from which the ranks were estimated.
We selected eight genes for qPCR validation from 
the top 100 over- or under-expressed using the crite-
ria that the range of ranks was generally below the 
25th percentile of the null and whose whose biologi-
cal  characteristics  were  of  interest  to  collaborators 
with expert knowledge of pancreatic cancer. Among 
the under-expressed genes includes NME4, a mem-
brane protein that shares homology with the putative 
metastasis suppressor gene NME1,20 and TALDO1, an 
enzyme that helps protect cellular integrity from oxy-
gen intermediates. Included in the over-expressed list 
are NSDHL, a protein involved in cholesterol synthe-
sis, ATAD2, and CEACAM5. ATAD2 and CEACAM5 
are both known to be up-regulated in cancer cells.21,22 
Figure 5 plots the fold changes measured by qPCR 
as a fourth platform together with the high-throughput 
fold changes. The direction of the average qPCR fold 
change  (up-regulated  or  down-regulated)  is  consis-
tent with the high-throughput platforms for 8/10 of 
the genes validated by qPCR, or 35/40 of the pairwise 
combinations. While the log2 fold-changes for Affyme-
trix and cDNA are often uncorrelated with SAGE, the 
direction of differential expression in SAGE is gener-
ally concordant for the set of qPCR-validated genes.
Among  the  qPCR-validated  genes  that  were 
under-expressed  in  metastatic  relative  to  primary 
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Figure 3. Plotted are the ranks of the average platform-specific ranks of the average fold-change in expression comparing metastatic to primary cell lines 
(x-axis) versus the range of the within-platform ranks (y-axis). The null distribution was obtained from 1000 permutations of the gene labels within each 
study. For each permutation, the range of ranks were ordered by the average rank. The shaded background depicts the density of the null distribution 
of the range of ranks at each rank of the average rank, with lighter shades denoting more densely plotted regions of the null. The black line is the 0.05 
quantile of the permutation distribution.Scharpf et al
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cell  lines,  the  qPCR-estimated  fold  changes  are 
overall correlated to the high-throughput measures 
of fold-changes, yet for a few of the comparisons 
the direction of fold change is discordant. In par-
ticular, the fold change estimated by qPCR for the 
ht-p1  comparison  is  greater  than  2  for  both  the 
TALDO1 and PAM genes, whereas the fold change 
is slightly below 1 in each of the high-throughput 
platforms  for  these  genes  (Fig.  5).  To  determine 
whether alternative splicing could be a contribut-
ing factor for the apparent discordance between the 
high-throughput platforms and qPCR, we mapped 
the probe sequences in each of the four platforms to 
exons and used Aceview to assess whether known 
isoforms could account for differences.23 The exon 
mappings for 3 genes in which discordance could 
plausibly  arise  from  alternative  splicing  are  dis-
played in Figure 6. For instance, qPCR primers for 
TALDO1 in the initial experiment (q1) map to the 
4–5  exon  junction. The  4–5  exon  junction  is  not 
spanned  by  the  high-throughput  platforms  and  is 
absent in some transcripts on Aceview (not shown). 
Repeating the qPCR-validation (q2) with different 
primers,  we  found  that  the  ht-p1  and  ht-ct  com-
parisons  for TALDO1  were  more  consistent  with 
the high-throughput platforms, yet fold-changes in 
expression remained discordant in others (6).
Discussion
This paper explores several approaches to assess con-
cordance of differential gene expression   measured 
from 2 primary and 2 metastatic pancreatic   cancer 
cell lines by 3 high-throughput platforms, with the 
goal  of  prioritizing  a  gene  list  for  validation  by 
qPCR. Pairwise scatter plots of the fold-changes in 
expression  highlight  the  challenges  of  this  analy-
sis,  with  near-zero  correlations  observed  between 
the intensity-based arrays (Affymetrix and cDNA) 
and  SAGE. As  qualitative  categories  of  differen-
tial expression can be less sensitive to technologi-
cal differences than quantitative measures of fold 
change, Kappa statistics plotted as a function of the 
threshold used to classify differential expression can 
provide a more robust assessment of concordance. 
For the pancreatic cancer analysis, Spearman cor-
relation  coefficients  and  Kappa  statistics  indicate 
moderate concordance of the Affymetrix and cDNA 
platforms,  but  low  concordance  with  SAGE.  As 
opposed to dropping SAGE from the analysis, we 
adopted an approach whereby genes prioritized by 
the rank of the average platform-specific ranks could 
be visualized along with the spread of the observed 
ranks. Plotted against a background estimated from 
a null that assumes that the the ranks were indepen-
dent across platforms, one can identify genes near 
the top and bottom of the list that are ranked more 
consistently than one would expect under the null. 
Such a visualization could also be applied to alterna-
tive rank-based schemes for prioritizing gene lists, 
and alternative measures of rank variability. Over-
all, the fold changes in expression as measured by 
the  high-throughput  platforms  for  10  genes  near 
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Figure 5. The observed fold changes of 10 genes selected for validation by qPCr. Fold changes less than 1/16 or greater than 16 were thresholded.
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the top (under-expressed in   metastatic) and bottom 
  (over-expressed  in  metastatic)  of  the  list  were  in 
agreement with the fold changes measured by qPCR. 
While batch- and technological artifacts unrelated 
to  the  sequence-characteristics  of  the  probes  in 
the  individual  platforms  are  likely  to  account  for 
much of the cross-platform discordance, hypotheses 
regarding  biological  mechanisms  for  discordance 
such as alternative splicing can be explored using 
the approaches discussed here.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Scharpf et al
264  Cancer Informatics 2010:9
Acknowledgments
This work was supported by grant 5T32ES012871 
from the U. S. National Institute of Environmental 
Health Sciences, grant DMS034211 from the NSF, 
and grant 5P30 CA06973-44 from the NIH.
Disclosure
This  manuscript  has  been  read  and  approved  by 
all authors. This paper is unique and is not under 
  consideration by any other publication and has not 
been  published  elsewhere.  The  authors  and  peer 
reviewers of this paper report no conflicts of   interest. 
The  authors  confirm  that  they  have  permission  to 
reproduce any copyrighted material.
References
  1.  Choi JK, Yu U, Kim S, Yoo OJ. Combining multiple microarray studies and 
modeling interstudy variation. Bioinformatics. 2003;19–1:I84–90.
  2.  Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-
  analysis of microarrays: interstudy validation of gene expression   profiles 
reveals pathway dysregulation in prostate cancer. 0008-5472 (Print) Journal 
Article Meta-Analysis. Cancer Res. 2002;62:4427–33.
  3.  Conlon Erin, Song Joon, Liu Jun. Bayesian models for pooling microarray 
studies with multiple sources of replications. BMC Bioinformatics. 2006; 
7:247.
  4.  Scharpf Robert B, Tjelmeland Håkon, Parmigiani Giovanni, Nobel Andrew. 
A  Bayesian  model  for  cross-study  differential  gene  expression.  JASA. 
2009;104:1295–310.
  5.  Parmigiani G. Measuring uncertainty in complex decision analysis models. 
Stat Methods Med Res. 2002;11:513–37.
  6.  Shen Ronglai, Ghosh Debashis, Chinnaiyan Arul. Prognostic   meta-signature 
of breast cancer developed by two-stage mixture modeling of microarray 
data. BMC Genomics. 2004;5:94.
  7.  Breitling Rainer, Herzyk Pawel. Rank-based methods as a non-parametric 
alternative of the T-statistic for the analysis of biological microarray data.   
J Bioinform Comput Biol. 2005;3:1171–89.
  8.  Hong  Fangxin,  Breitling  Rainer,  McEntee  Connor  W,  Wittner  Ben  S, 
  Nemhauser Jennifer L, Chory Joanne. RankProd: a bioconductor package 
for detecting differentially expressed genes in meta-analysis. Bioinformatics. 
2006;22:2825–7.
  9.  Elo Laura L, Filen Sanna, Lahesmaa Riitta, Aittokallio Tero. Reproducibility-
Optimized Test Statistic for Ranking Genes in Microarray Studies IEEE/
ACM Trans. Comput Biol Bioinformatics. 2008;5:423–31.
  10.  Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly Expressed Genes 
in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization 
and Comparison of the Transcription Profiles Obtained from Three Major 
Technologies. Cancer Research. 2003;63:8614–22.
  11.  Speed TP ed. Statistical Analysis of Gene Expression Microarray Data. 
  London: Chapman and Hall 2003.
  12.  Hruban  RH,  Goggins  M,  Parsons  J,  Kern  SE.  Progression  model  for 
  pancreatic cancer. Clin Cancer Res. 2000;6:2969–72.
  13.  Yang Yee Hwa, Dudoit Sandrine, Luu Percy, et al. Normalization for cDNA 
microarray data: A robust composite method addressing single and multiple 
slide systematic variation. Nucleic Acids Res. 2002;30:e15.
  14.  Scharpf  Robert  B,  Iacobuzio-Donahue  Christine  A,  Sneddon  Julie  B, 
  Parmigiani Giovanni. When should one subtract background fluorescence 
in 2-color microarrays? Biostatistics. 2007;8:695–707.
  15.  Carter  Scott  L,  Eklund Aron  C,  Mecham  Brigham H,  Kohane  Isaac  S, 
  Szallasi Zoltan. Redefini-tion of Affymetrix probe sets by sequence   overlap 
with cDNA microarray probes reduces cross-platform inconsistencies in 
cancer-associated  gene  expression  measurements.  BMC  Bioinformatics. 
2005;6:107.
  16.  Dai  Manhong, Wang  Pinglang,  Boyd Andrew  D,  et  al.  Evolving  gene/ 
transcript definitions signifi-cantly alter the interpretation of GeneChip data. 
Nucleic Acids Res. 2005;33:e175.
  17.  Cope  Leslie,  Zhong  Xiaogang,  Garrett  Elizabeth,  Parmigiani  Giovanni. 
MergeMaid:  R  tools  for  merging  and  cross-study  validation  of  gene 
  expression data. Stat Appl Genet Mol Biol. 2004;3:Article29.
  18.  Everitt BS. Moments of statistics kappa and weighted kappa. The British 
Journal of Mathematical and Statistical Psychology. 1968;21:97–103.
  19.  Breitling  Rainer,  Armengaud  Patrick,  Amtmann  Anna,  Herzyk  Pawel. 
Rank products: a simple, yet powerful, new method to detect   differentially 
regulated genes in replicated microarray experiments. FEBS Lett. 2004; 
573:83–92.
  20.  MacDonald NJ, Freije JM, Stracke ML, Manrow RE. Steeg PS. Site-directed 
mutagenesis of nm23-H1. Mutation of proline 96 or serine 120 abrogates its 
motility inhibitory activity upon transfection into human breast carcinoma 
cells. J Biol Chem. 1996;271:25107–16.
  21.  Zimmer R, Thomas P. Mutations in the carcinoembryonic antigen gene in 
colorectal cancer patients: implications on liver metastasis. Cancer Res. 
2001;61:2822–6.
  22.  Zou June X, Revenko Alexey S, Li Li B, Gemo Abigael T, Chen Hong-Wu. 
ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is 
required for coregulator occupancy and chromatin modification. Proc Natl 
Acad Sci U S A. 2007;104:18067–72.
  23.  Thierry-Mieg  Danielle,  Thierry-Mieg  Jean.  AceView:  a  comprehensive 
cDNA-supported  gene  and  transcripts  annotation.  Genome  Biol.  2006; 
7 Suppl 1:S12.1–1214.